Exposure to Ambient Particulate Matter Is Associated With Accelerated Functional Decline in Idiopathic Pulmonary Fibrosis

Chest

Volumn 153, Issue 5, 2018, Pages 1221-1228

  Winterbottom, Christopher J ^a   Shah, Rupal J ^d   Patterson, Karen C ^b   Kreider, Maryl E ^b   Panettieri, Reynold A ^e   Rivera Lebron, Belinda ^f   Miller, Wallace T ^c   Litzky, Leslie A ^b   Penning, Trevor M ^b   Heinlen, Krista ^b   Jackson, Tara ^b   Localio, A Russell ^b   Christie, Jason D ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

air pollution; environmental pollution; idiopathic pulmonary fibrosis; interstitial lung disease; pulmonary fibrosis

Indexed keywords

ADULT; AGED; AIR POLLUTION; AMBIENT AIR; ARTICLE; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); DISEASE COURSE; ENVIRONMENTAL EXPOSURE; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PARTICULATE MATTER; PRIORITY JOURNAL; SPIROMETRY; COMPLICATION; DISEASE EXACERBATION; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; TIME FACTOR; VERY ELDERLY; VITAL CAPACITY;

AGED; AGED, 80 AND OVER; AIR POLLUTION; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PARTICULATE MATTER; TIME FACTORS; VITAL CAPACITY;

EID: 85037824333     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2017.07.034     Document Type: Article

References (30)

1. Raghu, G., Collard, H.R., Egan, J.J., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:6 (2011), 788–824.
2. Hubbard, R., Lewis, S., Richards, K., Johnston, I., Britton, J., Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 347:8997 (1996), 284–289.
3. Taskar, V.S., Coultas, D.B., Is idiopathic pulmonary fibrosis an environmental disease?. Proc Am Thorac Soc 3:4 (2006), 293–298.
4. Miyake, Y., Sasaki, S., Yokoyama, T., et al. Occupational and environmental factors and idiopathic pulmonary fibrosis in Japan. Ann Occup Hyg 49:3 (2005), 259–265.
5. Baumgartner, K.B., Samet, J.M., Stidley, C.A., Colby, T.V., Waldron, J.A., Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 155:1 (1997), 242–248.
6. Jin, H.L., Dong, J.C., Pathogenesis of idiopathic pulmonary fibrosis: from initial apoptosis of epithelial cells to lung remodeling?. Chin Med J (Engl) 124:24 (2011), 4330–4338.
7. Uhal, B.D., Joshi, I., Hughes, W.F., Ramos, C., Pardo, A., Selman, M., Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic human lung. Am J Physiol 275:6 Pt 1 (1998), L1192–L1199.
8. Plataki, M., Koutsopoulos, A.V., Darivianaki, K., Delides, G., Siafakas, N.M., Bouros, D., Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis. Chest 127:1 (2005), 266–274.
9. Gunther, A., Korfei, M., Mahavadi, P., von der Beck, D., Ruppert, C., Markart, P., Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. Eur Respir Rev 21:124 (2012), 152–160.
10. Hoffmann, B., Moebus, S., Mohlenkamp, S., et al. Residential exposure to traffic is associated with coronary atherosclerosis. Circulation 116:5 (2007), 489–496.
11. Hoffmann, B., Moebus, S., Dragano, N., et al. Chronic residential exposure to particulate matter air pollution and systemic inflammatory markers. Environ Health Perspect 117:8 (2009), 1302–1308.
12. Volk, H.E., Lurmann, F., Penfold, B., Hertz-Picciotto, I., McConnell, R., Traffic-related air pollution, particulate matter, and autism. JAMA Psychiatry 70:1 (2013), 71–77.
13. Chen, H., Burnett, R.T., Kwong, J.C., et al. Risk of incident diabetes in relation to long-term exposure to fine particulate matter in Ontario, Canada. Environ Health Perspect 121:7 (2013), 804–810.
14. Kesavachandran, C., Pangtey, B.S., Bihari, V., et al. Particulate matter concentration in ambient air and its effects on lung functions among residents in the National Capital Region, India. Environ Monit Assess 185:2 (2013), 1265–1272.
15. Gan, W.Q., FitzGerald, J.M., Carlsten, C., Sadatsafavi, M., Brauer, M., Associations of ambient air pollution with chronic obstructive pulmonary disease hospitalization and mortality. Am J Respir Crit Care Med 187:7 (2013), 721–727.
16. Johannson, K.A., Vittinghoff, E., Lee, K., et al. Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. Eur Respir J 43:4 (2014), 1124–1131.
17. ArcGIS Desktop [computer program]. ESRI, Redlands, CA; 2013.
18. King, T.E. Jr., Bradford, W.Z., Castro-Bernardini, S., et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370:22 (2014), 2083–2092.
19. Richeldi, L., du Bois, R.M., Raghu, G., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370:22 (2014), 2071–2082.
20. Zappala, C.J., Latsi, P.I., Nicholson, A.G., et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 35:4 (2010), 830–836.
21. Latsi, P.I., du Bois, R.M., Nicholson, A.G., et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 168:5 (2003), 531–537.
22. Macintyre, N., Crapo, R.O., Viegi, G., et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 26:4 (2005), 720–735.
23. Wanger, J., Clausen, J.L., Coates, A., et al. Standardisation of the measurement of lung volumes. Eur Respir J 26:3 (2005), 511–522.
24. Miller, M.R., Hankinson, J., Brusasco, V., et al. Standardisation of spirometry. Eur Respir J 26:2 (2005), 319–338.
25. Miller, M.R., Crapo, R., Hankinson, J., et al. General considerations for lung function testing. Eur Respir J 26:1 (2005), 153–161.
26. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:1 (2002), 111–117.
27. Zhu, Y., Hinds, W.C., Kim, S., Sioutas, C., Concentration and size distribution of ultrafine particles near a major highway. J Air Waste Manag Assoc 52:9 (2002), 1032–1042.
28. Maldonado, G., Greenland, S., Simulation study of confounder-selection strategies. Am J Epidemiol 138:11 (1993), 923–936.
29. Baughman, R.P., Lower, E.E., Miller, M.A., Bejarano, P.A., Heffelfinger, S.C., Overexpression of transforming growth factor-alpha and epidermal growth factor-receptor in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 16:1 (1999), 57–61.
30. Seibold, M.A., Wise, A.L., Speer, M.C., et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 364:16 (2011), 1503–1512.